MarketWatch21 分钟
AbbVie’s disappointing schizophrenia drug trial bodes well for rival Bristol Myers ...
analysts said. On Monday AbbVie ABBV said that its Phase 2 trial investigating emraclidine as a once-daily oral monotherapy ...